At-home syphilis test kit market to grow $1.25b

Asia Pacific leads growth in at-home syphilis testing.

The At-Home Syphilis Testing Market is forecasted to have a growth of $1.245b by 2035, with a compound annual growth rate (CAGR) of 11.16%, a Future Market Insights (FMI) analysis said.

The outlook also highlighted the evolution of consumer behaviour and expansion of the global digital healthcare landscape.

The Asia Pacific region dominates the market due to the expanding digital health infrastructure and public health initiatives.

A MarketsandMarkets report said that it is also the fastest region with the growth in home healthcare as it is estimated to reach $473.8b by 2030 with a CAGR of 10.1%.

The market expansion strays from traditional clinic-based diagnostics as it is driven by the global necessity for more discreet, convenient, and accessible testing solutions amidst rising STI burdens, FMI said.

One of the growth factors is the increase of testing adherence by 30% to 50% due to the privacy and convenience of at-home test kits.

Blood sample tests also accounted for 63.2% share in 2025 for its accuracy in treponemal screening and strong clinical acceptance, making them the preferred format for both rapid and mail-in kits.

Rapid test kits factor in 46.7% share for its instant, finger-prick format that expedites screening without the need for a physical visit to a clinic.

App-based guidance, encrypted telehealth reporting, and automated follow-up systems simplify the process to treatment initiation and partner notification.

The Asia Pacific region dominates the market due to the expanding digital health infrastructure and public health initiatives.

"It directly addresses the core issues of stigma and access. This market is not just about selling test kits; it's about enabling a seamless, private pathway from screening to tele-consultation and treatment, which is essential for global disease management," an FMI analyst said.

The market is also focused on the quality, accuracy, and convenience, rather than pricing.

The report highlighted that the market would favor companies that can offer multipathogen STI self-testing portfolios and smoothly connect the user's result with virtual sexual-health clinics and digital prescriptions.